| Literature DB >> 35372422 |
Xiaoxiao Lu1, Jianhui Zhang1,2, Wentao Ma1, Lihua Xing1, Hanbing Ning3, Mengying Yao1.
Abstract
The incidence of non-HIV-infected Pneumocystis Jirovecii Pneumonia (PJP) is increasing. The prognosis for non-HIV PJP is poor and diagnostic tests are of lower sensitivity in non-HIV patients. Metagenomic next-generation sequencing (mNGS) was compared with routine detection assays, including Gomori methenamine silver (GMS) stain and polymerase chain reaction (PCR) technique. Specimens of 4 bronchoalveolar lavages (BAL) and 1 lung tissue samples were obtained from 4 non-HIV patients from our hospitals. Although both GMS and mNGS were positive for P. jirovecii with PCR as positive control, the testing time of mNGS was obviously shorter than GMS. Compared with the traditional GMS method, mNGS has absolute advantages. However, the issue with PJP presentations having atypical symptoms and ambiguous imaging features persists. Hence, the disease can easily be ignored. Secondly, PJP progresses rapidly in non-HIV-infected patients and can cause severe respiratory failure with unfavorable prognosis. This study affirms that mNGS can be used to quickly and accurately diagnose PJP, but a combination of clinical judgement of symptoms, laboratory testing, and imaging examination is required to make a comprehensive judgment along with mNGS test results.Entities:
Keywords: GMS; P. jirovecii; Pneumocystis jirovecii pneumonia; diagnosis; mNGS
Year: 2022 PMID: 35372422 PMCID: PMC8965517 DOI: 10.3389/fmed.2022.812005
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Clinical characteristics of patients.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| NO.1/female/78 | PCP | fever, cough, sputum, chest tightness, dyspnea | MPA | Yes | Yes |
| NO.2/female/77 | PCP | palpitations, dyspnea, chest tightness | AIH | Yes | Yes |
| NO.3/male/54 | PCP | fever, chest tightness, dyspnea | NS | Yes | No |
| NO.4/male/58 | PCP | fever, chest tightness, dyspnea | NS | Yes | Yes |
MPA, microscopic polyangiitis; AIH, autoimmune hepatitis; GC, glucocorticoids; ISA, immunosuppressant; NS, Nephrotic Syndrome.
Summary of laboratory test results and metagenomic next-generation sequencing (mNGS) results.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| 1 | BALF | 33 |
| 20,564 | |
| 2 | BALF, lung tissue | 15 |
|
| 1,319 (BALF), 297 (lung tissue) |
| 3 | BALF | 6 |
|
| 34 |
| 4 | BALF | 14 |
|
| 279 |
CMV, cytomegalovirus; EBV, Epstein Barr virus.
Figure 1(A) PCR detection for P. jirovecii DNA on bronchoalveolar lavage fluid (BALF) specimens. (B) PCR detection for plasmid.
Figure 2Arrowheads show P. jirovecii cysts which are round or oral. The cyst wall is darkened or brownish-black by GMS, while the content is almost colorless. (B) shows lung tissue specimen, (A,C,D) are BALF specimens.
Figure 3P. jirovecii appearances on Chest CT scan in patient 2 as multiple patchy and flocculent high-density shadows in both lungs.
Figure 4P. jirovecii appearances on Chest CT scan in patient 3 as a large number of meshwork shadows and multiple small nodules in both lungs.